Crossmark

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-018-0456-x

Published Online: 2019-01-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Baldeiras, Inês

Santana, Isabel

Leitão, Maria João

Vieira, Daniela

Duro, Diana

Mroczko, Barbara

Kornhuber, Johannes

Lewczuk, Piotr https://orcid.org/0000-0002-8101-6535
Funding

Funding for this research was provided by:

Innovative Medicines Initiative Joint Undertaking (EMIF 115372)

European Regional Development Fund (CENTRO-01-0145-FEDER-000008:BrainHealth 2020)

Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT (POCI-01-0145-FEDER-007440)

Portuguese Foundation for Science and Technology (PD/BD/135108/2017, SFRH/BD/52289/2013)
License Information

Text and Data Mining valid from 2019-01-05
More Information

Article History

Received: 5 October 2018

Accepted: 28 November 2018

First Online: 5 January 2019

Ethics approval and consent to participate

: The study was approved by the Ethics Board of Coimbra University Hospital. All subjects or responsible caregivers, whichever appropriate, gave their informed consent.

: Not Applicable.

: PL received consultation and/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, and Roche. BM received consultation and/or lecture honoraria from Roche, Cormay, and Biameditec.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.